| Name | Title | Contact Details |
|---|
Kyverna Therapeutics is pioneering a new class of therapies and cures for serious autoimmune diseases. Our therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of disease. Kyverna is venture-backed and located in the San Francisco East Bay.
Quick-Med Technologies is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The KPC Group is a Riverside, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack seeks to gain a deeper understanding of underlying cancer biology through its systems biology-based approach and develop new insights, therapeutics and diagnostics to improve outcomes for cancer patients. Merrimack has multiple oncology therapeutics in clinical development and additional candidates in late stage preclinical development. Merrimack has a New Drug Application under review for its lead product candidate, MM-398, for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy.
Ring`s research team has uncovered the world`s largest collection of commensal anelloviruses and are harnessing these natural viruses to target a wide array of diseases with significant unmet need. The unique biology of anelloviruses provides a foundation for a revolutionary new platform and a new class of programmable medicines.